BIRC5 and breast carcinoma: Although an increased expression of survivin in tumour tissues has been already demonstrated to correlate with a poor clinical outcome in a variety of malignancies [20-22], our results clearly indicated an analogous significant impact on prognosis of such a molecular alteration among T4 breast cancer patients.